| Literature DB >> 23751955 |
Shahinaz M Gadalla1, Carmem Sales-Bonfim, Jeanette Carreras, Blanche P Alter, Joseph H Antin, Mouhab Ayas, Prasad Bodhi, Jeffrey Davis, Stella M Davies, Eric Deconinck, H Joachim Deeg, Reggie E Duerst, Anders Fasth, Ardeshir Ghavamzadeh, Neelam Giri, Frederick D Goldman, E Anders Kolb, Robert Krance, Joanne Kurtzberg, Wing H Leung, Alok Srivastava, Reuven Or, Carol M Richman, Philip S Rosenberg, Jose Sanchez de Toledo Codina, Shalini Shenoy, Gerard Socié, Jakub Tolar, Kirsten M Williams, Mary Eapen, Sharon A Savage.
Abstract
We describe outcomes after allogeneic transplantation in 34 patients with dyskeratosis congenita who underwent transplantation between 1981 and 2009. The median age at transplantation was 13 years (range, 2 to 35). Approximately 50% of transplantations were from related donors. Bone marrow was the predominant source of stem cells (24 of 34). The day-28 probability of neutrophil recovery was 73% and the day-100 platelet recovery was 72%. The day-100 probability of grade II to IV acute GVHD and the 3-year probability of chronic graft-versus-host disease were 24% and 37%, respectively. The 10-year probability of survival was 30%; 14 patients were alive at last follow-up. Ten deaths occurred within 4 months from transplantation because of graft failure (n = 6) or other transplantation-related complications; 9 of these patients had undergone transplantation from mismatched related or from unrelated donors. Another 10 deaths occurred after 4 months; 6 of them occurred more than 5 years after transplantation, and 4 of these were attributed to pulmonary failure. Transplantation regimen intensity and transplantations from mismatched related or unrelated donors were associated with early mortality. Transplantation of grafts from HLA-matched siblings with cyclophosphamide-containing nonradiation regimens was associated with early low toxicity. Late mortality was attributed mainly to pulmonary complications and likely related to the underlying disease.Entities:
Keywords: Allogeneic transplantation; Dyskeratosis congenita; Long-term survival; Pulmonary toxicity
Mesh:
Year: 2013 PMID: 23751955 PMCID: PMC3736557 DOI: 10.1016/j.bbmt.2013.05.021
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742